A new program to speed drug development moved an Abbott Laboratories cancer drug through the first round of human testing six months faster than usual. The drug was the first to be tested under the National Cancer Institute's Experimental Therapeutics program, which aims to cut up to a year off the usual 10- to 12-year drug clearance process.

Related Summaries